Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases
Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases: A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Changsha, China, 410008
- Recruiting
- Xiangya Hospital
-
Contact:
- Zixi Jiang
- Phone Number: 13278883845
- Email: jiangzixi@csu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age over 16 years
- Diagnosed by 2 or more professional dermatologists
- Willing to underwent a new treatment modality
- Follow up is easy to conduct
Exclusion Criteria:
- Poor general condition
- Bleeding tendency
- Allergy to drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Traditional injection
Intralesional injection of drug by traditional injection needle.
This is the traditional approach for drug delivery recommended by international guidelines for each skin diseases.
|
For scar, the drug is triamcinolone acetonide.
Other Names:
|
|
EXPERIMENTAL: Piezoelectric drived microneedling
Intralesional injection of drug by piezoelectric drived microneedles.
|
Piezoelectric drived microneedling
For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short-term response
Time Frame: 1 week after treatment
|
This is a qualitative item which should be evaluated by comparing the general images and dermoscopic images pre-treatment and post-treatment carefully.
|
1 week after treatment
|
|
Long-term response
Time Frame: 1 month after treatment
|
This is a qualitative item which should be evaluated by comparing the general images and dermoscopic images pre-treatment and post-treatment carefully.
|
1 month after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain score during treatment
Time Frame: Immediately
|
Using visual analogue scale (score 0-10, 0=no pain, 10=unbearable pain) to evaluate the level of pain
|
Immediately
|
|
POSAS(The Patient and Observer Scar Assessment Scale) score
Time Frame: 1 month after treatment
|
A widely used scar scale for evaluating the severity of scar by both patients and dermatologists.
Score ranged from 11 to 110.
The higher score means severer condition of scar.
|
1 month after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Infections
- DNA Virus Infections
- Skin Diseases, Infectious
- Fibrosis
- Papillomavirus Infections
- Skin Diseases, Viral
- Tumor Virus Infections
- Cicatrix
- Skin Diseases
- Warts
- Cicatrix, Hypertrophic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Triamcinolone
- Aminolevulinic Acid
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
- Photosensitizing Agents
Other Study ID Numbers
Other Study ID Numbers
- XiangyaDerm0002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.